---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-25-003432"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:53:47.507991+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Relmada reports FY2024 net loss $80M; cash $44.8M; new Phase 2 programs NDV-01 and sepranolone

## Summary
- Q4 2024 net loss $18.6M ($0.62/sh) vs $25.1M ($0.84/sh) in Q4 2023; FY2024 net loss $80M ($2.65/sh) vs $98.8M ($3.28/sh).
- Cash and short-term investments $44.9M at Dec 31, 2024, down from $96.3M at Dec 31, 2023; runway into H1 2026 based on plans.
- Topline Phase 2 data for NDV-01 (bladder cancer) expected at AUA April 26-29, 2025; Phase 2b-ready sepranolone for Tourette syndrome.
- Re-evaluating further development of REL-P11 due to competitive landscape in metabolic disease.
- R&D expense FY2024 $46.2M, down from $54.8M; G&A $37.7M vs $48.9M, reflecting cost-saving measures.

## SEC filing metadata
- accession: 0001013762-25-003432
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000101376225003432/0001013762-25-003432-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000101376225003432/ea0236006-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-25-003432
- JSON: https://secwatch.observer/filing/0001013762-25-003432.json
- Plain text: https://secwatch.observer/filing/0001013762-25-003432.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.